Financial Performance - The company reported a significant narrowing of net loss by 55.16% year-on-year, despite ongoing pressure on gross margins from hepatitis B products due to procurement policies[4]. - Revenue continued to grow, with an overall increase in gross margin exceeding 4 percentage points[4]. - The net cash flow from operating activities turned positive, indicating improved operational quality[4]. - The company's operating revenue for 2024 was ¥441,457,673.77, representing a 4.43% increase compared to ¥422,714,889.10 in 2023[18]. - The net loss attributable to shareholders decreased by 55.16% to ¥156,304,356.74 in 2024 from ¥348,589,843.18 in 2023[18]. - The net cash flow from operating activities improved significantly to ¥20,707,723.30 in 2024, compared to a negative cash flow of ¥174,595,576.92 in 2023, marking an increase of 111.86%[18]. - The total assets at the end of 2024 were ¥1,438,807,956.07, a decrease of 10.88% from ¥1,614,481,833.09 at the end of 2023[18]. - The company reported a basic earnings per share of -¥0.9814 for 2024, an improvement of 55.16% from -¥2.1887 in 2023[18]. - The weighted average return on equity improved to -35.66% in 2024 from -49.90% in 2023, indicating a 14.24% increase[18]. - The company’s net profit before non-recurring gains and losses remained negative, indicating ongoing challenges in achieving profitability[18]. Research and Development - The company plans to maintain its innovation strategy, which has led to increased financial expenses and asset impairment losses[4]. - In 2024, the approval of 48 innovative drugs and 55 rare disease drugs was achieved, along with 106 pediatric drug products, indicating a significant acceleration in drug approval processes[30]. - The company has developed five major antiviral drugs for hepatitis B, including Adefovir, Lamivudine, Entecavir, Tenofovir, and Prodrug Tenofovir, enhancing its competitive advantage in the market[32]. - The innovative drug "Tai Zhong Ding" was approved in 2023, marking the company's first approved innovative product and showcasing its capability in full-cycle drug development[34]. - The company’s hepatitis treatment drug GST-HG141 completed Phase II clinical trials and was included in the national breakthrough therapy category, reflecting its advanced position in hepatitis drug development[34]. - The company is committed to expanding its product pipeline through both internal development and external acquisitions, focusing on innovative drug research and production[36]. - The company has multiple innovative antiviral drug candidates in various stages of clinical trials, enhancing its portfolio and market competitiveness in the hepatitis treatment sector[60]. - The company has established a strong innovation pipeline with a focus on antiviral and liver health drugs, aiming to fill industry gaps and fulfill social responsibilities[64]. Market and Industry Trends - The pharmaceutical industry is projected to grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2028, with global drug spending expected to reach approximately $2.2 trillion by 2028[27]. - In 2023, the overall pharmaceutical market in China reached ¥16,333 billion, with a year-on-year growth of 4.3%[28]. - The market for hepatitis B treatment has significant growth potential, with current diagnosis and treatment rates at only 22% and 15%, respectively, compared to WHO targets[38]. Corporate Governance and Management - The company has established a complete and independent governance structure, ensuring compliance with relevant laws and regulations[131]. - The board of directors consists of 9 members, including 3 independent directors, fulfilling legal requirements[134]. - The company has a performance evaluation and incentive mechanism for senior management, linking compensation directly to company performance[138]. - The company maintains independent financial management, with no guarantees provided for shareholders or related parties[141]. - The company has a dedicated investor relations management system, ensuring effective communication with investors[137]. Environmental Responsibility - The company has invested approximately 920,000 RMB in environmental governance and protection for 2024, which includes costs for soil monitoring, pollution source monitoring, and maintenance of pollution control facilities[189]. - The company has obtained an environmental discharge permit valid from November 22, 2024, to November 21, 2029, following the approval from the environmental protection department[183]. - The company has not experienced any environmental violations or accidents as of December 2024, and has established an effective environmental risk management system[186]. - The company’s wastewater treatment process includes a dual A/O + Fenton reagent treatment method, ensuring compliance with discharge standards[185]. Strategic Partnerships and Collaborations - The company established a strategic partnership with the Round Mountain Fund, enhancing its competitive position in the health industry and promoting the integration of traditional Chinese medicine[72]. - The company is actively collaborating with global research institutions to advance its innovative drug development strategy, aiming for a leading position in the industry[49]. Future Outlook and Strategy - Future development strategies and operational plans are subject to market conditions and uncertainties, and do not constitute profit forecasts[5]. - The company aims to achieve a high-quality, leapfrog development by 2025, focusing on both generic and innovative drugs[113]. - The company will deepen marketing reforms and focus on key product breakthroughs, particularly in liver disease products and new traditional Chinese medicine IPs[114]. - The company intends to enhance capital operations and promote financing and acquisitions to support innovative drug clinical research funding needs[115].

广生堂（300436）公告，2024年营业收入4.41亿元，同比增长4.43%。归属于上市公司股东的净亏损 1.56亿元，去年同期净亏损3.49亿元。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

大家好欢迎参加华云医药团队广声堂创新药交流会目前座上会者均处于静音状态请开始播报声明请参会人员务必注意本次电话会议交流内容仅限参会人员内部参考任何机构或个人不得以任何形式对电话会议任何内容进行泄露或外发请勿以任何方式索要泄露散布转发电话会议纪要任何泄露电话会议纪要等信息的行为均为侵权行为 花言证券保留追究泄露转发者法律责任的权利好的各位投资人下午好我们本次这个电话会议是关于这个广声堂的这个近期的情况交流啊因为广声堂呢是这个我们近期一直在终点跟踪的一个这个标的啊近期公司也是这个创下应该那些比较好的一个变化所以本次呢由我们和这个国军团队 一起来主持这个电话会议本次呢我们有先请到这个公司的这个豪华高管然后我们本次的这个电话会议就分这个两个环节第一个就请公司的庄总给大家做个近期的介绍然后这个剩下就是我们那个提问啊提问环节来庄总有请 感谢华远感谢国泰军安也感谢今天下午参会的关注管生团的各位投资朋友我是管生团的副总经理庄成明今天下午管生团这边参会的人员有首席科学家胡科博士高级研发总监吴文强博士董事会秘书张清禾还有我们管生中林的董事长张玉华博士 然后最后我们也邀请到了管生谈的董事长李国平先生所以下午对我们会对投资人所关注的 ...

近期，广生堂（300436.SZ）发布定增预案，拟向不超过35名特定对象发行股票不超过4778.01万股，募 集资金总额不超过9.77亿元。 《中国经营报》记者注意到，广生堂自2015年上市以来，累计通过IPO、可转债、定增等方式募资超20 亿元，但创新药研发进展缓慢，且此前多个募投项目因"市场环境变化"或"技术障碍"终止。 从此前的经验看，前两次募资的低效执行已为公司敲响警钟；从现实困境看，流动性危机和高负债率让 其转型之路充满不确定性。此次定增能否扭转局面，仍是未知数。 针对此次定增的具体情况，本报记者日前向广生堂方面致函采访，其证券部相关负责人表示，由于公司 临近年报披露期，且定增项目正处于资料准备的密集时期，因此没有过多时间对采访问题进行回复。 前次募投项目"烂尾" 公开资料显示，广生堂主要从事核苷类抗乙肝病毒药物的研发、生产与销售，主要产品包括阿甘定—阿 德福韦酯、贺甘定—拉米夫定、恩甘定—恩替卡韦等核苷类抗乙肝病毒药物。 广生堂方面表示，通过本次向特定对象发行A股股票，有助于进一步扩充公司的资金来源，加快上述创 新药研发进程，扩充公司新产品管线，为公司创造新的利润增长点，增强公司抵御市场风险的能力 ...

前次定增募资未果后，时隔近两年，广生堂（300436）再度抛出了定增募资计划。 广生堂最新公告显示，公司拟向特定对象发行A股股票拟募集资金总额不超过约9.77亿元（含本数），扣除发行费用后全部用于创新药 研发项目、中药传统名方产业化项目以及补充流动资金，拟分别投入募资额5.98亿元、8849.05万元、2.9亿元。 其中，创新药研发项目包括创新药GST-HG141的III期临床研究及上市注册项目、GST-HG131联合GST-HG141的II期及III期临床研究及上 市注册项目。 此外，公司通过收购中药传统名方并建设配套生产线，通过优质工艺、高品质道地药材提升产品品质，以实现更高的附加值，适应国内 快速增长的大健康消费升级需求。 拟定增募资背后，广生堂近年来业绩持续亏损，于2021—2023年连亏三年。财务数据显示，2021—2023年，广生堂实现的营业收入分别 约为3.7亿元、3.86亿元、4.23亿元，对应实现的归属净利润分别为-0.35亿元、-1.27亿元、-3.49亿元。 2024年，广生堂预计继续亏损。公司2024年业绩预告显示，预计实现营业收入4.35亿元至4.6亿元，归属净利润为-1.25亿元至 ...

Core Viewpoint - Guangshentang (300436) announced a private placement plan to issue up to 47.78 million shares, raising no more than 977 million yuan, aimed at funding innovative drug research, traditional Chinese medicine industrialization, and supplementing working capital [1] Group 1: Fundraising and Projects - The private placement will help expand the company's funding sources, accelerate innovative drug development, and create new profit growth points [1] - The total investment for the innovative drug research project is 631 million yuan, with 598 million yuan planned to be funded by the raised capital [2] - The traditional Chinese medicine industrialization project has a total investment of 105 million yuan, with 88.49 million yuan to be funded by the raised capital [2] Group 2: Previous Fundraising Efforts - This is the third private placement since 2020, with previous attempts yielding unsatisfactory results [2][3] - The 2020 private placement raised 514 million yuan, but the projects funded did not meet revenue expectations, leading to significant underperformance [3] - The 2023 private placement was withdrawn due to regulatory changes and strategic considerations [3] Group 3: Financial Performance and Challenges - Guangshentang has faced continuous losses for four years, with a significant decline in revenue from its main products due to price drops from centralized procurement policies [4] - Research and development expenses have increased significantly, accounting for 18.62% to 48.08% of revenue from 2021 to 2023 [5] - The company reported losses of 34.89 million yuan, 127 million yuan, and 349 million yuan from 2021 to 2023, with a projected loss of 125 million to 163 million yuan for 2024 [5] Group 4: Cash Flow and Debt Situation - The company has experienced negative cash flow from operating activities, with net cash flow of -177.65 million yuan in 2021 and -174.36 million yuan in 2024 [6] - The cash reserves have decreased from approximately 200 million yuan at the end of 2023 to 127 million yuan by the end of the third quarter of 2024 [6] - The asset-liability ratio has increased significantly, reaching 67.28% by the end of September 2024 [6]

| 项目名称 | 投资金额 | 拟使用募集资金 | 事集资金是否属 | | --- | --- | --- | --- | | | | 金额 | 于资本化阶段 | | -、创新药研发项目 | 63,100.60 | 59,837.60 | 是 | | 二、中药传统名方产业化 | 10,525.29 | 8,849.05 | 是 | | 三、补充流动资金 | 29,000.00 | 29,000.00 | 否 | | 合计: | 102,625.89 | 97,686.65 | | 截至预案公告日，公司尚未确定具体的发行对象，因而无法确定发行对象与公司的关系。 中国经济网北京4月3日讯广生堂（300436）(300436.SZ)昨晚披露《2025年度向特定对象发行A股股票预 案》称，本次向特定对象发行A股股票的发行对象为不超过35名(含)的特定投资者，包括符合中国证监 会规定的证券投资基金管理公司、证券公司、信托公司、财务公司、保险机构投资者、合格境外机构投 资者、人民币合格境外机构投资者，以及符合中国证监会规定的其他法人、自然人或其他合格的投资者 等。其中，证券投资基金管理公司、证券公司、合格境外机构投资者、 ...

Core Viewpoint - The company plans to issue A-shares to specific investors in 2025, which may dilute immediate returns for existing shareholders, but it has proposed measures to compensate for this dilution and ensure the protection of minority investors' rights [2][6][10]. Financial Impact Analysis - The company estimates a net profit range of -195 million to -157 million yuan for 2024, with a potential 50% increase in losses compared to 2024 [3][4]. - Three scenarios for 2025 net profit projections are analyzed: a 50% increase in losses, maintaining 2024 levels, and a 50% reduction in losses [4][5]. - The projected basic and diluted earnings per share (EPS) under these scenarios range from -0.90 to -1.36 yuan [4][5]. Necessity and Reasonableness of the Issuance - The issuance aligns with relevant policies and the company's strategic development plan, indicating its necessity and feasibility [6][7]. Use of Raised Funds - The raised funds will be allocated to "innovative drug R&D," "industrialization of traditional Chinese medicine," and "supplementing working capital," supporting the company's transition from generic drugs to innovative drugs and health consumption sectors [7][8][9]. Company’s Preparedness for Investment Projects - The company has accumulated significant experience and technical barriers in the liver health and antiviral sectors, with a strong talent pool and ongoing patent applications for its drug candidates [9]. Measures to Mitigate Dilution of Immediate Returns - The company will enhance its competitive advantages and profitability, actively implement fundraising projects, and strengthen fund management to mitigate the dilution of immediate returns for shareholders [10][11][12]. Commitments from Key Stakeholders - The company's board and senior management have committed to fulfilling the proposed compensation measures for shareholders, ensuring no unfair benefit is provided to other entities [14][15].

证券代码：300436 证券简称：广生堂 公告编号：2025016 福建广生堂药业股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 司（以下简称"公司"）第五届董事会第七次会议审议通过，决定于 2025 年 4 月 一、会议召开的基本情况 公司召开 2025 年第一次临时股东大会；会议召集程序符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 （1）现场会议召开时间：2025 年 4 月 18 日（星期五）14:00 （2）网络投票时间： 日 9:15—15:00 期间的任意时间。 召开，公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （1）在股权登记日持有公司股份的股东。 于股权登记日下午收市时在中国结算深圳分公司登记在册的公司全体股东 均有权出席股东大会，并可以以书面形式委托代理人出席会议和参加表决，该股 东代理人不必是本公司股东。 （2）公司董事、监事、高级管理人员。 （3）公司聘请的见证律师及相关人员。 根据《公司法》 ...

证券代码：300436 证券简称：广生堂 公告编号：2025015 福建广生堂药业股份有限公司 完整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 福建广生堂药业股份有限公司（以下简称"公司"）第五届监事会第六次会 议于 2025 年 3 月 30 日以邮件、电话等形式发出通知，于 2025 年 4 月 2 日在福 建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二 期 16 号楼 13F 会议室以现场结合通讯表决方式召开。会议由监事会主席主持， 会议应出席监事 3 人，实际出席监事 3 人。会议的召开符合《公司法》和《公司 章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于公司符合向特定对象发行A股股票条件的议案》 经核查，监事会认为：公司符合现行法律法规和规范性文件中关于向特定对 象发行 A 股股票的有关规定，具备向特定对象发行 A 股股票的条件。 表决结果：有效表决票数 3 票，同意 3 票，反对 0 票，弃权 0 票。 本议案需提交股东大会审议。 （二）审议通过《关于公司2025年度向特定对象发行A股股票方案的议案》 （逐项表决） 监事会对本议案下各子议 ...